Eli Lilly, MiNA Therapeutics Join in Research Collaboration
By Michael Dabaie
Eli Lilly and Co. and MiNA Therapeutics Ltd. said Tuesday they
are in a global research collaboration to develop novel drug
candidates using MiNA's proprietary small activating RNA technology
Under the terms of the agreement, MiNA will use its saRNA
platform to research up to five targets selected by Lilly to
address diseases across Lilly's therapeutic focus areas.
Lilly will be responsible for preclinical and clinical
development of candidates and will retain exclusive
commercialization rights for any products resulting from the
MiNA will receive a $25 million upfront payment and is eligible
to receive potential development and commercialization milestones
up to a total of $245 million per target, as well as tiered
royalties from the low-single to low-double digits on product
Lilly said there would be no change to its 2021 non-GAAP
earnings per share guidance as a result of this transaction.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
May 11, 2021 07:52 ET (11:52 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.